Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Oct 5:4:16.
doi: 10.1186/1478-7547-4-16.

Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure

Franz P Hessel  1
Affiliations

Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure

Franz P Hessel. Cost Eff Resour Alloc. .

Abstract

Background: Acute-on-chronic liver failure (ACLF) is a life threatening acute decompensation of a pre-existing chronic liver disease. The artificial liver support system MARS is a new emerging therapeutic option possible to be implemented in routine care of these patients. The medical efficacy of MARS has been demonstrated in first clinical studies, but economic aspects have so far not been investigated. Objective of this study was to estimate the cost-effectiveness of MARS.

Methods: In a clinical cohort trial with a prospective follow-up of 3 years 33 ACLF-patients treated with MARS were compared to 46 controls. Survival, health-related quality of life as well as direct medical costs for in- and outpatient treatment from a health care system perspective were determined. Based on the differences in outcome and indirect costs the cost-effectiveness of MARS expressed as incremental costs per life year gained and incremental costs per QALY gained was estimated.

Results: The average initial intervention costs for MARS were 14600 EUR per patient treated. Direct medical costs over 3 years follow up were overall 40000 EUR per patient treated with MARS respectively 12700 EUR in controls. The 3 year survival rate after MARS was 52% compared to 17% in controls. Kaplan-Meier analysis of cumulated survival probability showed a highly significant difference in favour of MARS. Incremental costs per life-year gained were 31400 EUR; incremental costs per QALY gained were 47200 EUR.

Conclusion: The results after 3 years follow-up of the first economic evaluation study of MARS based on empirical patient data are presented. Although high initial treatment costs for MARS occur the significantly better survival seen in this study led to reasonable costs per live year gained. Further randomized controlled trials investigating the medical efficacy and the cost-effectiveness are recommended.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan Meier Analysis after 3 years follow-up.
See this image and copyright information in PMC

References

    1. Boker KH. [Acute liver failure] Internist (Berl) 2001;42:545–54, 556-62. - PMC - PubMed
    1. Lee WM. Acute liver failure in the United States. Semin Liver Dis. 2003;23:217–226. doi: 10.1055/s-2003-42641. - DOI - PubMed
    1. Bauer M, Winning J, Kortgen A. Liver failure. Curr Opin Anaesthesiol. 2005;18:111–116. doi: 10.1097/01.aco.0000162827.74270.32. - DOI - PubMed
    1. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol. 2005;100:468–475. doi: 10.1111/j.1572-0241.2005.40864.x. - DOI - PubMed
    1. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs. 2002;26:103–110. doi: 10.1046/j.1525-1594.2002.06822.x. - DOI - PubMed

LinkOut - more resources